Tiny Nanoparticles Could Make Big Impact for Cornea Transplants

ByConnor Hodde

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants 12. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance.  The nanoparticle loaded with medication could eliminate the need for a patient to remember to take their medicine – often multiple doses per hour – after a surgery, alleviating compliance risk. These types of drug delivery systems could be paired with other drugs and used in other conditions, such as glaucoma, macular degeneration and corneal ulcers, among others.

Read the entire article here

Similar Posts

Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration.

ByConnor Hodde

Retinal degenerative diseases are major causes of untreatable blindness, and novel approaches to treatment are being sought actively. Here we explored the activation of a unique protein, sigma 1 receptor (Sig1R), in the treatment of PRC loss because of its multifaceted role in cellular survival.  We used Pde6βrd10 (rd10) mice, which harbor a mutation in…

Mayo Clinic work shows possible Lucentis side effect

ByConnor Hodde

At the Amercian Academy of Opthalmology 115th Annual Meeting, findings were presented from a retrospective study conducted after a Mayo Clinic opthalmologist noticed an increase in intraoccular pressure (IOP) in her patients using Genentech’ (Roche) Lucentis (ranibizumab), an FDA-approved drug for the treatment of age-related macular degeneration (AMD). MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial…

EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™

ByPhotoreceptor

EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…

Scientists find a way to ‘shrink’ blind spot in human eye

ByConnor Hodde

The optic nerve that sends visual signals to the brain must pass through the retina which creates a hole in that light-sensitive layer of tissue. When images project to that precise location, we miss them. This blind spot can be ‘shrunk’ despite the fact that the hole in our visual field cannot be. The findings…

Study Findings Help Design Next-Generation Nanocarriers

ByConnor Hodde

Researchers believe that atomic-scale design of pharmaceuticals will be instrumental in producing more accurate and efficient drugs. Nanocarriers are engineered particles capable of holding tiny molecules inside their hollow interiors. Antibodies, which are bonded to the outer surface of these nanocarriers, function as markers to target specific cells or tissues or supply drugs to infected…

Cell transplant restores sight in mice

ByConnor Hodde

Experimental cell transplants can improve the sight of visually impaired mice, it has been widely reported. The Independent called the research behind the news a “major step towards cure for blindness”, while The Guardian said the work is “the first demonstration that cell transplants can restore useful vision”. During the research, scientists used mice bred…